Intravitreal Ziv-aflibercept: Initial Clinical Experience

摘要: CONCLUSIONZiv-aflibercept appears to be a promising, safe, low-cost alternate anti-VEGF therapy for retinal diseases, especially in countries where intravitreal aflibercept is not available. However, further studies are warranted to evaluate its dosing, efficacy, and safety with long-term follow-up in a larger sample size in various retinal disorders. RP